NEW YORK (GenomeWeb News) – PrognosDx Health and the Molecular Medicine Research Institute announced recently a broad collaborative R&D agreement aimed at using PrognosDx's technology for the development of a new class of epigenetic therapeutics.
The deal provides Palo Alto, Calif.-based PrognosDx with resources to launch CLIA lab services, including a prostate cancer prognosis test and predictive tests for other cancers, the partners said.
PrognosDx now also will have a "platform for introductions to select pharma partners" for the development of new epigenetic therapeutics based on its recent "breakthrough discoveries." Initially, it and MMRI will focus on treatments for hormone refractory prostate cancer using PrognosDx's genome-wide histone modification-based biomarkers and cellular metabolism-related therapeutic insights to analyze clinical samples and carry out preclinical studies. They also plan to collaborate with academic centers on breast and gastrointestinal cancers.
As a result of the collaboration, Edward Amento, founder and executive director of MMRI, has joined PrognosDx's board.
PrognosDx uses epigenetic technology for the analysis of global histone modifications, allowing physicians to tailor cancer treatments for individual patients. Sunnyvale, Calif.-based MMRI is a non-profit institute which offers preclinical and clinical services. Its 31,000-square-foot lab has molecular biology, immunohistochemistry, flow cytometry, medicinal chemistry, cell culture, preclinical models, and other technical resources.